Home » Stocks » KRON

Kronos Bio, Inc. (KRON)

Stock Price: $31.70 USD -0.78 (-2.40%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
After-hours: $31.47 -0.23 (-0.73%) Jan 25, 4:00 PM
Market Cap 1.78B
Revenue (ttm) n/a
Net Income (ttm) -25.05M
Shares Out 52.75M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $31.70
Previous Close $32.48
Change ($) -0.78
Change (%) -2.40%
Day's Open 32.82
Day's Range 31.44 - 33.39
Day's Volume 65,231
52-Week Range 26.68 - 38.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

MYC amplification found in approximately 30% of solid tumors

GlobeNewsWire - 2 months ago

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today ann...

GlobeNewsWire - 2 months ago

Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of N PM1-mutated acute myeloid leukemia

GlobeNewsWire - 2 months ago

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today anno...

Seeking Alpha - 2 months ago

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...

Other stocks mentioned: AYLA, FUBO, GAN, INTZ, KC, SPRB, STTK
Benzinga - 3 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CCL, BAM, FUBO, HEI, STTK
GlobeNewsWire - 3 months ago

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development...

Seeking Alpha - 3 months ago

U.S. IPO Weekly Recap: Healthcare Dominates A 7 IPO Week

Other stocks mentioned: FUBO, INTZ, MAACU, MUDSU, NGACU, SPRB, STTK
Market Watch - 3 months ago

Shares of Kronos Bio Inc. soared in their public debut, as they opened 50% above the initial public offering price. The stock's first trade was at $28.50 at 11:58 a.m.

Benzinga - 3 months ago

This week has down with 6 IPOS scheduled for Thursday and Friday. FuboTV: Sport first live tv streaming company Fubo TV (OTC: FUBO) is uplisting to the Nasdaq.

Other stocks mentioned: FUBO
Market Watch - 3 months ago

Kronos Bio Inc. priced its upsized initial public offering at $19 a share, above its $16 to $18 price range. The California-based biotech sold 13.2 million shares to raise about $250.8 million.

GlobeNewsWire - 3 months ago

SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cance...

Market Watch - 3 months ago

Kronos Bio Inc. KRON, disclosed Thursday that its initial public offering was upsized by about 28%, as the California-based biopharmaceutical now looks to raise up to $236.8 million

About KRON

Kronos Bio, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified ... [Read more...]

Industry
Research and Development in Biotechnology
IPO Date
Oct 9, 2020
CEO
Dr. Norbert W. Bischofberger
Employees
61
Stock Exchange
NASDAQ
Ticker Symbol
KRON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Kronos Bio stock is "Buy." The 12-month stock price forecast is 43.67, which is an increase of 37.76% from the latest price.

Price Target
$43.67
(37.76% upside)
Analyst Consensus: Buy